Perceptive Advisors has significantly expanded its investment in Praxis Precision Medicines, acquiring an additional 431,432 shares valued at approximately $80.34 million during the fourth quarter of 2025. The move elevates the fund's total position to $588.30 million, establishing Praxis as its largest holding at 10.8% of assets under management.
The substantial investment reflects confidence in Praxis's clinical progress and financial strength. The biotech company has submitted two New Drug Applications to the FDA and maintains a robust cash position of $1.547 billion, providing a substantial runway for ongoing operations and development activities. The company's advancing pipeline has resonated with investors, as evidenced by the stock's 320% appreciation over the past twelve months.
Perceptive Advisors' increased conviction in the company underscores growing investor interest in Praxis as it moves closer to potential commercialization of its pipeline candidates. The substantial cash balance positions the company to fund operations through key regulatory and clinical milestones without requiring near-term capital raises.